The CYP3A5*1/*3 single nucleotide polymorphism (SNP) determines the extent of drug interaction between tacrolimus and ï¬‚uconazole in renal transplant recipientsH. de Jonge, M. Naesens, Y. Vanrenterghem, D. R. Kuypers
Ann Transplant 2008; 13(1): 34-35 :: ID: 880191
Background: Drug interactions between calcineurin-inhibitors and azole antifungals are characterized by a large clinical variability. The aim of this study was to examine the effect of CYP3A4, CYP3A5 and MDR1 SNPs on changes in tacrolimus trough concentrations and daily dose in renal transplant recipients treated with ï¬‚uconazole.
Material/Methods: Out of 753 renal transplant recipients treated with tacrolimus, 29 patients were identified who received ï¬‚uconazole treatment. These patients were genotyped for CYP3A4*1/*1B, CYP3A5*1/*3, MDR1 C3435T and G2677T/A and the effect of these SNPs on tacrolimus trough concentrations and dosing during ï¬‚uconazole treatment was examined.
Results: Dose-corrected tacrolimus C0 did not increase significantly from baseline (1.26±1.23-fold) in heterozygous CYP3A5*1 carriers (n=6) during ï¬‚uconazole therapy, as opposed to CYP3A5*3 homozygous patients (n=23) (3.28±2.34-fold; p=0.04 between CYP3A5*3/*3 and CYP3A5*3/*1 genotypes ). CYP3A5*3 homozygotes demonstrated a significant decrease in body weight-corrected tacrolimus dose during ï¬‚uconazole administration (-54.7±23.7% from baseline, p<0.05) as opposed to heterozygous carriers of CYP3A5*1 (-25.1±29.9%; p=0.07 between CYP3A5*3/*3 and CYP3A5*3/*1 genotypes). These findings were not inï¬‚uenced by ï¬‚uconazole dose or duration of treatment. More CYP3A5*3 homozygous patients were exposed to tacrolimus C0 â‰¥15 ng/mL during ï¬‚uconazole therapy compared to CYP3A5*1 carriers (73.9% vs. 16.7%, p=0.01).
Conclusions: Renal transplant recipients with the CYP3A5*3/*3 genotype (non-expressers), are more susceptible for ï¬‚uconazole-induced inhibition of tacrolimus metabolism as opposed to CYP3A5*1 carriers (expressers). Identification of this genetic determinant affecting the extent of this CYP3A-mediated drug interaction could potentially help to better manage drug interactions between tacrolimus and ï¬‚uconazole.
Keywords: Tacrolimus, transplant, Broca
20 Jan 2022 : Original articleImpact on Waitlist Outcomes from Changes in the Medical Eligibility of Candidates for Simultaneous Liver-Ki...
Ann Transplant In Press; DOI: 10.12659/AOT.934850
19 Jan 2022 : Original articleCarbohydrate Metabolism Disorders in Relation to Cardiac Allograft Vasculopathy (CAV) Intensification in He...
Ann Transplant In Press; DOI: 10.12659/AOT.933420
18 Jan 2022 : Original articlePLGA+Fe₃O₄+PFP Nanoparticles Drug-Delivery Demonstrates Potential Anti-Tumor Effects on Tumor Cells
Ann Transplant In Press; DOI: 10.12659/AOT.933246
Most Viewed Current Articles
29 Dec 2021 : Original articleEfficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...
Ann Transplant 2021; 26:e933588
22 Dec 2021 : Original articleComparison of Coronary Artery Calcium Scoring with Dobutamine Stress Echo for Detection of Coronary Artery ...
Ann Transplant 2021; 26:e934163
12 Jan 2022 : Original articleRisk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...
Ann Transplant 2022; 27:e934738